Effect of vitamin B6 on pain, disease severity, and psychological profile of fibromyalgia patients; a randomized, double-blinded clinical trial

• Published in: BMC musculoskeletal disorders Vol. 23; no. 1; pp. 1 - 664
• Main Authors: Ghavidel-Parsa, Banafsheh, Naeimi, Arvin, Gharibpoor, Faeze, Sattari, Nazila, Jafari, Atefeh, Masooleh, Irandokht Shenavar, Montazeri, Ali
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 13.07.2022; BioMed Central; BMC
• Subjects: Anxiety; Blood; Blood platelets; Care and treatment; Causes of; Clinical trials; Depression, Mental; Development and progression; Diabetes; Diabetic neuropathy; Disease; Fibromyalgia; Inflammation; Laboratories; Medical students; Migraine; Musculoskeletal diseases; Neurotransmitters; Neutrophils; Pain; Pain perception; Pathogenesis; Patients; Placebos; Psychological aspects; Pyridoxine; Questionnaires; Rheumatology; Sample size; Statistical analysis; Testing; Vitamin B6; United States; Iran
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-022-05637-7

Abstract Background Given the role of vitamin B6 on pronociceptive/antinociceptive neurotransmitters balance, metabolic reactions, and inflammation, it is important to clarify the effect of vitamin B6 on pain and psychological disturbance in fibromyalgia (FM). This study aimed to evaluate whether an 80-mg daily dose of vitamin B6 improves pain, disease severity and psychological symptoms of FM compared to a placebo. Methods This randomized, double-blinded, placebo-controlled trial was performed on the FM patients whose diagnosis was confirmed by a rheumatologist based on the 2016 American College of Rheumatology (ACR). 90 Patients were randomized to receive either vitamin B6 (80 mg daily) or placebo in a 1:1 ratio, with a permuted block size of 30 stratified by disease severity. Primary outcomes included the Revised Fibromyalgia Impact Questionnaire (FIQR), Hospital Anxiety and Depression Scale (HADS), 12-item short-form health survey (SF-12), and pain visual analog scale (pain-VAS)). The mean differences in outcomes (before and after treatment) were compared between the vitamin B6 and placebo groups using an independent T-test. An ANCOVA model adjusted for baseline outcome value was also provided to compare the outcomes between the two groups. Results Of 90 eligible patients, 60 patients (31 patients in vitamin B6 and 29 in the placebo group) completed the trial. Overall, the FIQR, pain-VAS, and HADS-anxiety scores improved after treatment in both vitamin B6 and placebo groups; However, there was no statistically significant intergroup difference regarding primary outcomes. ANCOVA model also showed no difference in the treatment effects. Conclusions Our results showed no priority for vitamin B6 over placebo in FM patients. Considering the potential ameliorating role of vitamin B6 on pain and psychological symptoms, acknowledgment of vitamin B6 as a relatively safe adjuvant treatment needs larger future studies. Trial registration Iranian Registry of Clinical Trials: IRCT20200920048782N2 on 2021/10/04.